Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | GRK6 | P43250 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776265 | 0.90 | HTR1A (0.42) | FLT3KARS1JAK2TRPV3KIT | |
| SCHEMBL16776270 | 0.86 | ABL1 (0.42) | KARS1JAK2KITSRCHTR1A | |
| SCHEMBL16776190 | 0.85 | FAAH (0.37) | FAAH | |
| SCHEMBL16776264 | 0.83 | SLC27A1 (0.35) | JAK2TRPV3KITHTR1AHTR7 | |
| SCHEMBL16776474 | 0.83 | FAAH (0.39) | FAAH | |
| SCHEMBL16776200 | 0.82 | FAAH (0.39) | FAAH | |
| SCHEMBL16776055 | 0.82 | KARS1 (0.49) | FAAHKARS1JAK2KITHTR1A | |
| SCHEMBL16775993 | 0.81 | ABL1 (0.43) | KARS1JAK2TRPV3KITHTR1A | |
| SCHEMBL16775987 | 0.80 | KARS1 (0.36) | KARS1JAK2KITHTR1AHTR7 | |
| SCHEMBL16776041 | 0.80 | FAAH (0.40) | FAAHFLT3KARS1JAK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 977/4885FLT3 319/4885KARS1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.